Huang Long, Ling Wang, Hai Su, Jinsong Xu, Juxiang Li, Qiang Peng, Yifei Dong, Xiaoshu Cheng
{"title":"他汀类药物可抑制高胆固醇血症患者循环RAS活性的增加。","authors":"Huang Long, Ling Wang, Hai Su, Jinsong Xu, Juxiang Li, Qiang Peng, Yifei Dong, Xiaoshu Cheng","doi":"10.1177/1470320313483349","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this paper is to investigate a profile on circulatory renin-angiotensin system (RAS) activity in hypercholesterolemic (HC) patients treated with statins.</p><p><strong>Methods: </strong>Eighteen primary HC patients and 18 sex- and age-matched healthy adults were included in this study as controls. Total cholesterol (TC), triglyceride (TG), LDL-C, blood glucose, angiotensin-converting enzyme (ACE) activity, and angiotensin II (Ang II) levels were measured before and four and eight weeks after beginning statin treatment in the HC group. Similar measurements were taken in the control group at baseline.</p><p><strong>Results: </strong>At baseline, TC, TG and LDL-C levels, as well as ACE activity and Ang II concentrations, were significantly higher in the HC group than in the control group. Based on the baseline data collection of 36 participants, there were significant positive correlations between ACE activity and TC (r = 0.54) or LDL-C (r = 0.51), and between Ang II level and TC (r = 0.34) or LDL-C (r = 0.27). TC, LDL-C, Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, p < 0.05) levels and ACE activity (108.9 ± 51.9 vs 180.1 ± 71.3 U/L, p < 0.05) were decreased in HC patients eight weeks after starting statin treatment. In HC patients, RAS activity correlated positively with TC and LDL-C levels before and after treatment.</p><p><strong>Conclusions: </strong>In HC patients, lowering serum cholesterol with statins is associated with decreased circulatory RAS activity.</p>","PeriodicalId":520698,"journal":{"name":"Journal of the renin-angiotensin-aldosterone system : JRAAS","volume":" ","pages":"126-30"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320313483349","citationCount":"5","resultStr":"{\"title\":\"Increased circulatory RAS activity can be inhibited by statins in patients with hypercholesterolemia.\",\"authors\":\"Huang Long, Ling Wang, Hai Su, Jinsong Xu, Juxiang Li, Qiang Peng, Yifei Dong, Xiaoshu Cheng\",\"doi\":\"10.1177/1470320313483349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The objective of this paper is to investigate a profile on circulatory renin-angiotensin system (RAS) activity in hypercholesterolemic (HC) patients treated with statins.</p><p><strong>Methods: </strong>Eighteen primary HC patients and 18 sex- and age-matched healthy adults were included in this study as controls. Total cholesterol (TC), triglyceride (TG), LDL-C, blood glucose, angiotensin-converting enzyme (ACE) activity, and angiotensin II (Ang II) levels were measured before and four and eight weeks after beginning statin treatment in the HC group. Similar measurements were taken in the control group at baseline.</p><p><strong>Results: </strong>At baseline, TC, TG and LDL-C levels, as well as ACE activity and Ang II concentrations, were significantly higher in the HC group than in the control group. Based on the baseline data collection of 36 participants, there were significant positive correlations between ACE activity and TC (r = 0.54) or LDL-C (r = 0.51), and between Ang II level and TC (r = 0.34) or LDL-C (r = 0.27). TC, LDL-C, Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, p < 0.05) levels and ACE activity (108.9 ± 51.9 vs 180.1 ± 71.3 U/L, p < 0.05) were decreased in HC patients eight weeks after starting statin treatment. In HC patients, RAS activity correlated positively with TC and LDL-C levels before and after treatment.</p><p><strong>Conclusions: </strong>In HC patients, lowering serum cholesterol with statins is associated with decreased circulatory RAS activity.</p>\",\"PeriodicalId\":520698,\"journal\":{\"name\":\"Journal of the renin-angiotensin-aldosterone system : JRAAS\",\"volume\":\" \",\"pages\":\"126-30\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/1470320313483349\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the renin-angiotensin-aldosterone system : JRAAS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1470320313483349\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/3/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the renin-angiotensin-aldosterone system : JRAAS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1470320313483349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/3/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
摘要
目的:研究他汀类药物治疗高胆固醇血症(HC)患者循环肾素-血管紧张素系统(RAS)活性的变化。方法:18例原发性HC患者和18例性别、年龄相匹配的健康成人作为对照。HC组患者在开始他汀类药物治疗前、4周和8周测量总胆固醇(TC)、甘油三酯(TG)、LDL-C、血糖、血管紧张素转换酶(ACE)活性和血管紧张素II (Ang II)水平。对照组在基线时也进行了类似的测量。结果:在基线时,HC组TC、TG、LDL-C水平以及ACE活性和Ang II浓度均显著高于对照组。根据36名参与者的基线数据收集,ACE活性与TC (r = 0.54)或LDL-C (r = 0.51), Ang II水平与TC (r = 0.34)或LDL-C (r = 0.27)之间存在显著正相关。HC患者在开始他汀类药物治疗8周后,TC、LDL-C、Ang II水平(35.46±14.49 vs 71.10±20.47 pg/ml, p < 0.05)和ACE活性(108.9±51.9 vs 180.1±71.3 U/L, p < 0.05)下降。HC患者治疗前后RAS活性与TC、LDL-C水平呈正相关。结论:在HC患者中,他汀类药物降低血清胆固醇与降低循环RAS活性相关。
Increased circulatory RAS activity can be inhibited by statins in patients with hypercholesterolemia.
Objective: The objective of this paper is to investigate a profile on circulatory renin-angiotensin system (RAS) activity in hypercholesterolemic (HC) patients treated with statins.
Methods: Eighteen primary HC patients and 18 sex- and age-matched healthy adults were included in this study as controls. Total cholesterol (TC), triglyceride (TG), LDL-C, blood glucose, angiotensin-converting enzyme (ACE) activity, and angiotensin II (Ang II) levels were measured before and four and eight weeks after beginning statin treatment in the HC group. Similar measurements were taken in the control group at baseline.
Results: At baseline, TC, TG and LDL-C levels, as well as ACE activity and Ang II concentrations, were significantly higher in the HC group than in the control group. Based on the baseline data collection of 36 participants, there were significant positive correlations between ACE activity and TC (r = 0.54) or LDL-C (r = 0.51), and between Ang II level and TC (r = 0.34) or LDL-C (r = 0.27). TC, LDL-C, Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, p < 0.05) levels and ACE activity (108.9 ± 51.9 vs 180.1 ± 71.3 U/L, p < 0.05) were decreased in HC patients eight weeks after starting statin treatment. In HC patients, RAS activity correlated positively with TC and LDL-C levels before and after treatment.
Conclusions: In HC patients, lowering serum cholesterol with statins is associated with decreased circulatory RAS activity.